Boehringer's leukemia candidate wins breakthrough status from FDA

09/19/2013 | Healio · PharmaTimes (U.K.)

Boehringer Ingelheim's polo-like kinase inhibitor volasertib won breakthrough-therapy designation from the FDA as a potential treatment for acute myeloid leukemia. The approval was based on data from a midstage trial that showed volasertib, in combination with low-dose cytarabine, improved overall and event-free survival compared with cytarabine alone.

View Full Article in:

Healio · PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC